Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.2.3.20NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.30NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DV.6.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FK.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HH.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.22.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GY.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HW.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.46NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GB.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.72NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.86NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.41.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GS.4.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JF.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JG.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBBNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.23.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.21.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.42NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.19NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.44NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FU.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FV.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GJ.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.22.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FE.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBL.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.56NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.1.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used